MedPath

Prediction of outcomes and response to treatments with an ultrasensitive method for assessing intratumor epigenetic heterogeneity in colorectal cancer

Not Applicable
Completed
Conditions
Colorectal cancer
Registration Number
JPRN-UMIN000021191
Lead Sponsor
Juntendo University Faculty of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients do not meet the inclusion criteria 2.Patients without histologically confirmed cancer 3.Patients whom investigators consider to be ineligible

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The detection rates of epigenetic heterogeneity in primary tumor and plasma from colorectal cancer patients with Methylation-sensitive high resolution melt(MS-HRM).
Secondary Outcome Measures
NameTimeMethod
1.To investigate the diffenrences in the detection rates between quantitative methylation specific PCR (qMSP) and MS-HRM 2.To investigate the correlations between epigenetic heterogeneity and gene expression in primary tumor from colorectal cancer patients
© Copyright 2025. All Rights Reserved by MedPath